Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32664709
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32664709
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Clin+Exp+Pediatr
2020 ; 63
(7
): 239-250
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Immunopathogenesis of COVID-19 and early immunomodulators
#MMPMID32664709
Lee KY
; Rhim JW
; Kang JH
Clin Exp Pediatr
2020[Jul]; 63
(7
): 239-250
PMID32664709
show ga
The novel coronavirus disease 2019 (COVID-19) is spreading globally. Although its
etiologic agent is discovered as severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2), there are many unsolved issues in COVID-19 and other infectious
diseases. The causes of different clinical phenotypes and incubation periods
among individuals, species specificity, and cytokine storm with lymphopenia as
well as the mechanism of damage to organ cells are unknown. It has been suggested
that in viral pneumonia, virus itself is not a direct cause of acute lung injury;
rather, aberrant immune reactions of the host to the insults from viral infection
are responsible. According to its epidemiological and clinical characteristics,
SARS-CoV-2 may be a virus with low virulence in nature that has adapted to the
human species. Current immunological concepts have limited ability to explain
such unsolved issues, and a presumed immunopathogenesis of COVID-19 is presented
under the proteinhomeostasis-system hypothesis. Every disease, including
COVID-19, has etiological substances controlled by the host immune system
according to size and biochemical properties. Patients with severe pneumonia
caused by SARS-CoV-2 show more severe hypercytokinemia with corresponding
lymphocytopenia than patients with mild pneumonia; thus, early immunomodulator
treatment, including corticosteroids, has been considered. However, current
guidelines recommend their use only for patients with advanced pneumonia or acute
respiratory distress syndrome. Since the immunopathogenesis of pneumonia may be
the same for all patients regardless of age or severity and the critical
immune-mediated lung injury may begin in the early stage of the disease, early
immunomodulator treatment, including corticosteroids and intravenous
immunoglobulin, can help reduce morbidity and possibly mortality rates of older
patients with underlying conditions.